NICE technology appraisal guidance
Issued: October 2009
TA183
Topotecan for the treatment of recurrent and stage IVB cervical cancer
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta183
Important information about this guidance
This guidance was developed using the NICE single technology appraisals process: www.nice.org.uk/aboutnice/howwework/devnicetech/developing_nice_technology_appraisals.jsp